Index

abstinence, 51
beneficial effects of, 20
acute psychotic symptoms, 122
acute toxic psychosis, 140
addiction, methamphetamine
CBT, 170
cocained treatment, 170
contingency management, 170
outcomes, 169–170
treatment, 169–170
adolescence, cannabis use among, schizophrenia in, 152–153
Advisory Committee on the Misuse of Drugs (ACMD), 52
alcohol use
as DD element in Europe, 232–233
in older people, 104–105
early-onset category, 106
excessive alcohol use, complications of, 106–107
media representation of information on, 104–105
problem drinkers, 106
sensible limits, 106
schizophrenia people, within mental health service settings, 22–23
alcohol and mood disorders, 76–85, See also Medication
harm, alcohol and mental illness, 76–77
presentation, 77–78
alcohol use, 78
anaemia, 77
appetite, 77
early morning wakening, 77
loss of libido, 78
Wernicke–Korsakoff syndrome, 77
amphetamines, 10, 15, 116–118, 122, 140
anticholinergic substances, 9
antidepressants, 32, 78
antisocial personality disorders, 18, 89
Assertive Community Treatment (ACT) model, 67, 205
assessment, 6–8
general considerations in, 5
personality disorders, 92–93
comprehensive assessment, 92
structured treatment models, 92
assortative mating, 10
Australia, DD in, 212–227
Australia’s responses to, 221
Australian health care system, structure of, 221
barriers to better outcomes for, 217–218
contributing factors, 217–218
‘Can Do’ – managing mental health and substance use in general practice, 223–224
‘Communities of Youth Services’ (CYS) activities, 224
consumer and carer demand, 212–213
co-occurring disorders, treatment for, 216–217
drivers for system change, 212
harms associated with, 213–216
headspace, 224–225
improved services for people with drug and alcohol problems and mental illness, 223
indigenous Australians, 218–219
mental health services in Australia (MHCA), 212–213
national comorbidity initiative, 221–223
completed projects, 222
current projects, 222
national level responses to DD, 221
prevalence of estimation, 214
forensic populations, 216
general population, 214
in persons in primary care, 215
in persons receiving treatment for a substance use disorder, 215
Australasia, DD in (cont’d)
in rural Australia, contributing factors, 217–218
attitudinal, 220
service access, 220
structural, 220
workforce, 220
rural and remote regions of Australia, 219–220
state level responses, 225–227
Victoria’s responses to dual diagnosis, 225–226
unwanted outcomes associated with, 213–216

‘Baby boomers’, 103
benzodiazepines, 108–109
blood-borne infections, 179–180
borderline personality disorders (BPD), 89
in women, 131–132
bupropion, 169
Caldicott principles, 42
cannabis use and psychosis, 118, 140, 147–159, 177
in adolescence, 152–153
among schizophrenia people, 151
drug-induced psychosis, 152
exacerbating psychotic illness, 154
interventions for, 155–158
cannabis and psychosis intervention (CAP), 156
group programmes, 156–157
motivational interviewing (MI), 155–156
two-session standard psychiatric interview, 156
legal issues, 148, See also penalties here
Misuse of Drugs Act 1971, 148
links between, 151–155
neurophysiological changes, 155
penalties
for adults in possession of, 149
for dealing, 149
for possession, 149
for production, 149
for supply, 149
for trafficking, 149
for young people in possession of, 149
physical effects, 150
prodromal symptoms of psychosis (PROD), 153
psychological effects, 149–150
risks associated with, 150
safety issues, 150
self-medication hypothesis, 154
stress-vulnerability theory or interaction hypothesis, 154
tetrahydrocannabinol (THC), 148
ways of affecting the user, 148–149
ways of using, 148
Care Programme Approach (CPA), 42, 91
Cartesian philosophical concept, 187
causal relationship, public health and DD, 178–180
children, MA in, 167
cholinergic pathways, 11
chronic hallucinosis induced by substance use, 142
clinical risk assessment, 39–41
demographic information in, 40
harm reduction strategies, 40
recovery-based approach, 40
clozapine, 126
cocaine, 118
cocaine hallucinosis, 118
cocaine-induced paranoia, 121
cocaine-induced psychosis, 118
cocaine-using schizophrenia people, 19
Cognitive behaviour therapy (CBT), 71–72
Cognitive behavioural integrated treatment (C-BIT), 68
commissioning services for users with DD, 243–248
background, 243–244
Drug Action Team (DAT), 246
history of commissioning, 244–246
‘internal market’, 244
implications for, 246–248
Local implementation Team (LIT), 246
overview and scrutiny committees (OSCs), 246
‘post code lottery’, 244
primary care trusts (PCTs), 244
world class commissioning, 245–246
common aetiology, 10
co-morbid personality disorder, 94
co-morbid psychotic illness, 16
co-morbid substance misuse, 190
‘Comorbidity’, 4
comorbidity between psychotic illness and substance misuse, 18
comorbidity or complexity, question of, 186–194, See also Primary care perspective
Comprehensive, Continuous, Integrated System of Care (CCISC) model, 182
‘Communities of Youth Services’ (CYS) activities, 224
conduct disorder, 18
consumer perspectives, 27–35, See also
Psychiatric wards
diagnosis, 29, 32
drug and alcohol services and mental health, contrasts in, 30–32
approach to ‘therapy’, 30–31
staff, make-up of, 30
dual diagnosis and policy, 33–35
human experience and medicine, 27–28
human rights, 28–29
involuntary patient admission, 30–32
language of mental illness, 28
treatment, 28–29, 32–33
two worlds, 29–30
voluntary in-patient admission, 30–32
contingency management, 72
co-occurring disorders
in Australasia, treatment for, 216–217
treatment for, 207
‘Cradle to the grave’ care, 190
‘DD aware’, 33
Data Protection Act 1998, 42
definition, 4–5
destitutionalisation effects, schizophrenia
population substance misuse, 20–21
delirium tremens (DT), 142
depression, 9, 79
‘Demographic transition’, 102–103
detoxification, 7, 10
diagnosis, consumer perspectives, 28–29, 32
discrepancy development, in motivational interviewing (MI), 60
disulfiram, 79
domestic violence, DD and, 135
dopamine, 121, 140–141
 dopaminergic neurotransmitter system, 17
drinking among schizophrenia, 19
Drug Misuse Act 1971, 103
drug-induced psychosis, 139–144
acute toxic psychosis, 140
prevalence of DD, 139–140
psychotic illness and, 142–144
anxiety reactions, 143
chronic hallucinosis induced by substance use, 142
drug-induced relapse, 142
intoxication, 142
pathoplastic reactions, 142
withdrawal states, 142
‘recreational’ drugs, 141
self-medication, 141
stimulant use and, 117–121
co-cain induced paranoia, 121
dopamine, 121
flashbacks, 120
Khat-related illness difficult, 120
methamphetamine psychosis, 120
positive symptoms, 119
sensitisation to substances, 120
short-lived schizophreniform illness, 120
substance use and psychosis, relationship between, 140–141
true drug-induced psychosis, 143
drug-induced relapse of functional psychotic illness, 142
drug-related harm among mentally ill people, reducing, 51–56, See also Harm reduction approaches
definition, 52–53
evidence-based approaches, 51
future, question of, 55–56
harm reduction, 52–53
interventions and approaches, 51–52
with mentally ill individuals, 53–54
five-stage intervention model, 53
motivation-based approaches, 53
needle and syringe exchange programmes, 52
drugs use, in schizophrenia people, within mental health service settings, 22–23
DSM III-R substance abuse disorder, 15
dual diagnosis, 179–180
dysphoria, 168
ecstacy users, 122
poly substance use among, 119
psychosis in, 119
education development, 253–254
effective treatments for substance misuse, 91
principles, 92
empathy expression, in motivational interviewing (MI), 60
Epidemiologic Catchment Area (ECA) study, 5, 14
Europe, DD in, 230–241
Czechoslovakia, 231
elements of DD, 232
alcohol, 232–233
care and treatment responses, 235–237
HIV/AIDS, 234–235
illicit drugs, 233
problems and solutions, 237–240
triple diagnosis, 234–235
Germany, 231
historical context, 230–232
poverty and mental health, 231
social context, 230–232
Soviet Union, 230
evidence-based treatment, 69
existing psychotic illnesses, stimulants use by, 122–124
explanatory models for dual diagnosis, 13–23
families
interventions, 72
women with DD, impact on, 133–134
Hidden Harm report, 133
female prison service, DD within, 135–136, See also Women and DD
five-stage intervention harm reduction model, 53
flusoxetin, 169

gender differences in DD, 131–133
gender-specific services, 136–137
general practice care, 190–191
General Practice Research Database (GPRD), 177
genetic factors, and dual diagnosis, relationship, 17
group therapies, 70–71

hallucination, 169
hallucinogen misuse, 15
harm reduction approaches, 52–53
definition, 52–53
with mentally ill individuals, 53–54
five-stage intervention model, 53
motivation-based approaches, 53
needle and syringe exchange programmes, 52
harm, alcohol and mental illness, 76–77
Hepatitis B (HBV), 179
Hepatitis C (HCV), 179

holistic risk assessment, 42
human experience and medicine, 27–28
human immunodeficiency virus (HIV), 180
human rights, consumer perspectives, 28–29
hypersomnia, 168
hypotheses, 8–11
common aetiology, 10
dual primary diagnosis, 10
mental illness is primary and substance misuse is secondary, 8
primary substance misuse with psychiatric consequences, 9

imipramine, 169
indigenous Australians, 218–219
indigenous substance use, 218–219
individual therapies, 70
infections and DD, 181–183
blood-borne infections, 179–180
causal relationship, 178–180
criteria for, 179
dual diagnosis, 179–180
epidemiology, 176–178
ethnicity, 178
Hepatitis B (HBV), 179
Hepatitis C (HCV), 179
human immunodeficiency virus (HIV), 180
infections, 181–183
CCISC model, 182
intervention, 181–183
needle exchange programmes (NEP) in prevention, 182
prevention, 181–183

primary prevention, 181
secondary prevention, 181–182
‘stages of change’ model, 182–183
system-wide approach, 182
tertiary prevention, 182
intravenous drug use (IVDU), 177
self harm, 177
suicide, 177
treatment for BBV, 180–181
initial problems in dual diagnosis, 16–17
difficulties in establishing temporal sequence, 16
in-patient care, 256–257
integrated care models, 203–204
Intensive Outpatient Programs (IOP), 205
intoxication in functional psychotic illness, 142
in MA, 168–169
intravenous drug use (IVDU), 177
‘Involuntary treatment’, 32–33

ketamine effect on people with and without schizophrenia, 123
Khat-related illness difficult, 120
language of mental illness, 28
legal issues in cannabis use, 148
long-term psychotic illness, 118
media representation of information on alcohol, 104–105
medication and dual diagnosis, 78–80
antidepressants, 78
disulfiram, 79
psychotropic medication, 78
selective serotonin reuptake inhibitors (SSRIs), 79
mental health and substance misuse care, 192–193
mental illness, stimulants and, 121–122
ecstasy, 122
mental illness/health problems, 3–6
initial assessment, 7
methamphetamine (MA) and mental health, 120, 163–171
addiction outcomes, 169–170
treatment, 169–170
anxiety, 169
brief intervention by physicians, 166
case studies, 164–165
in children, 167
community based programs, 166
continuation of, 165–168
hallucination, 169
initiation, 165–168
interpersonal violence, 167
intoxication, 168–169
mood disturbance, 169
Index

paranoia, 169
in pregnant women, 166
psychiatric illness, 168–169
screening, 166
withdrawal, 168–169
3,4-Methylenedioxymethamphetamine, 141
methylenedioxyamphetamine (MDA), 116
methylenedioxy-N-methamphetamine (MDMA), 116
Michigan Alcohol Screening Test (MAST-G), 107
Misuse of Drugs Act 1971, 97, 148
mood disorders, 76–85, See also Alcohol and
mood disorders
motivational approaches, 69–70
motivational interviewing (MI), 58–65, 155
description, 58–61
full-blown resumption of previous
behaviour, 60
opening strategies, 61
affirming, 61
open-ended questions, 61
reflective listening, 61
summarising, 61
principles, 60
developing discrepancy, 60
expressing empathy, 60
roll with resistance, 60–61
supporting self-efficacy, 61
short-lived resumption of previous
behaviour, 60
‘Stages of Change’ model, 59
motivation-based harm reduction approach, 53

National Toxicology Program Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR 2005), 167
needle exchange programmes (NEP), 182
neurobiological basis of dual diagnosis, question of, 17–18
neuroleptic (‘antipsychotic’) medications, 32
neurophysiological changes, 155
‘No Right Door’ policy, 34
‘NoWrong Door’, 33
non-cocaine-using schizophrenia people, 19–20
non-ecstasy users, poly substance use among, 119
North America, DD in, 199–207
challenges, 206–207
coccurring disorders, treatment for, 207
historical context, 200–201
insurance programmes, 202
issues, 206–207
lifetime substance abuse disorders, 199
MICA (Mentally ill chemical abusers) models, 201
prevalence, 199–200
public policy considerations, 201–203
quality and accessibility to care, 202
research, 205–206
socio-cultural considerations, 201–203
treatment approaches, 203–205
Assertive Community Treatment (ACT) model, 205
integrated care models, 203–204
Intensive Outpatient Programs (IOP), 205
obstacle to, 203
partial hospitalisation, 205
self-help group approach, 205
twelve-step programmes, 205

olanzapine, 126
older people, DD in, 102–113
alcohol use among, 104–106
eyear-onset category, 106
excessive alcohol use, complications of, 106–107
media representation of information on, 104–105
problem drinkers, 106
sensible limits, 106
assessment, 107
‘baby boomers’, 103
eyear-onset drinking, case study, 109–112
an increasing population, 102–103
late-onset drinking, case study, 111–112
over-the-counter medication (OTC), 107–108
perception of old age, 105
policy framework, 103–104
prescribed medication, 108–111
benzodiazepines, 108–109
screening, 107
under-reporting, 107
orofacial tardive dyskinesia, 20
over-the-counter medication (OTC), 107–108
paranoia, 169
paranoid schizophrenia, 118
pathoplastic reactions in functional
psychotic illness, 142
penalties associated with cannabis, 149
for adults in possession of, 149
for dealing, 149
for possession, 149
for production, 149
for supply, 149
for trafficking, 149
for young people in possession of, 149
perception of old age, 105
retirement, 105
personality disorders, 4, 89–100
antisocial personality disorders (ASPD), 89
assessment, 92–93
comprehensive assessment, 92, 95
structured treatment models, 92
borderline personality disorders (BPD), 89
description, 90–91
dual diagnosis mediated by, 18
intervention approaches, 91–92
prevalence, 89
service delivery, 89–90
stages of change model, 93–99
action, 93
contemplation, 93
decision, 93
factors to consider, 97–98
guidance, 94
maintenance, 93
relapse, 93
screening, 95–96
therapeutic principles, 99–100
treatment, 91–92
physical effects of cannabis use, 150
physical health care, 191–192
policy framework, for DD in older people, 103–104
poly substance use
among ecstasy users, 119
among non-ecstasy users, 119
and personality disorder, 89–100, See also Personality disorder treatments for, 91
post-traumatic stress disorder (PTSD), 130
practice, 254–257
mental health and substance abuse services, assessment in, 255–256
organisation of services, 256
in-patient care, 256–257
prevention, 254–255
primary care, 255
pregnant women, MA in, 166
prescribed medication, for older people, 108–111
benzodiazepines, 108–109
presentation, alcohol and mental illness, 77–78
alcohol use, 78
anaemia, 77
appetite, 77
eyearly morning wakening, 77
loss of libido, 78
Wernicke–Korsakoff syndrome, 77
primary care perspective on DD, 186–194
co-morbid substance misuse, 190
‘cradle to the grave’ care, 190
epidemiology, 188–190
evidence-based approach, 190
general practice care, 190–191
limitations in, 193–194
mental health and substance misuse care, 192–193
physical health care, 191–192
policy framework, 188
potential in, 193–194
primary care trusts (PCTs), 244
substance misuse and mental illness, relation between, 189
primary dual diagnosis, 10
primary substance misuse with psychiatric consequences, 9–10
prodromal symptoms of psychosis (PROD), 153
psychiatric illness, 168–169
psychiatric wards
drug and alcohol services and mental health, contrasts in, 30–32
approach to ‘therapy’, 30–31
staff, make-up of, 30
involuntary patient admission, 30–32
voluntary in-patient admission, 30–32
psychological effects of cannabis use, 149–150
in adolescence, 152–153
among schizophrenia people, 151
drug-induced psychosis, 152
exacerbating psychotic illness, 154
interventions for, 155–158
 cannabis and psychosis intervention (CAP), 156
group programmes, 156–157
motivational interviewing (MI), 155–156
two-session standard psychiatric interview, 156
legal issues, 148, See also penalties here Misuse of Drugs Act 1971, 148
links between, 151–155
neurophysiological changes, 155
penalties
for adults in possession of, 149
for dealing, 149
for possession, 149
for production, 149
for supply, 149
for trafficking, 149
for young people in possession of, 149
physical effects, 150
prodromal symptoms of psychosis (PROD), 153
psychological effects, 149–150
risks associated with, 150
safety issues, 150
self-medication hypothesis, 154
stress-vulnerability theory or interaction hypothesis, 154
tetrahydrocannabinol (THC), 148
ways of affecting the user, 148–149
ways of using, 148
psychological interventions, 67–73
  ACT models, 67
cognitive behaviour therapy (CBT), 71–72
  evidence for, 68–70
evidence-based treatment, 69
  family interventions, 72
group therapies, 70–71
  individual therapies, 70
  motivational approaches, 69–70
  nature of, 67–68
  primary disorder, 69
  relapse prevention, 71–72
  secondary disorder, 69
type of, 67–68
psychosis, 32
  stimulant use and, 116–127
psychotic illness/disorders, 16–17
  cannabis use exacerbating, 154
  and drug and alcohol use, 142–144, See also Drug-induced psychosis in general population and substance misuse people, comparison, 14–16
psychotropic medication, 78
public health and DD, 176–184
causal relationship, 178–180
criteria for, 179
dual diagnosis, 179–180
epidemiology, 176–178
ethnicity, 178
Hepatitis B (HBV), 179
Hepatitis C (HCV), 179
human immunodeficiency virus (HIV), 180
  infections, 181–183
  CCISC model, 182
  needle exchange programmes (NEP) in prevention, 182
  prevention, 181–183
  primary prevention, 181
  secondary prevention, 181–182
  'stages of change' model, 182–183
  system-wide approach, 182
  tertiary prevention, 182
  intravenous drug use (IVDU), 177
  self harm, 177
  suicide, 177
  treatment for BBV, 180–181
public policy considerations, in North America, 201–203
  ratings scales for stimulant use, 125
  recognition, 6–8
  general considerations in, 5
  recovery-based approach in risk assessment, 40
  'Recreational' drugs, 141
  relapse prevention, 71–72
research, 250–252
  need for, 251–252
resistance roll, in motivational interviewing (MI), 60–61
retirement, 105
risk assessment and management, 39–49, See also Clinical risk assessment principles, 41–42
  Caldicott principles, 42
  Care Programme Approach (CPA), 42
  Data Protection Act 1998, 42
  Department of Health provides (DH 2007), 41
  holistic risk assessment, 42
  process of, 42–43
  care planning, 43
  communication, 43
deciding which risk factors can be modified, 42
defining the risks, 42
evaluating the risks, 42
  identifying who is at risk, 42
  information gathering, 42
  resource implications, 43
  review, 43
risk factors for addiction, 8–9
  safety issues in cannabis use, 150
  schizophrenia people, 10, 14–16, 20–22, 122
  alcohol use, within mental health service settings, 22–23
  cannabis prevalence among, 151
  cocaine-using, 19
  drugs use, within mental health service settings, 22–23
  ketamine effect on, 123
  medication side effects, 20
  non-cocaine-using, 19–20
  substance misuse in, 20–21
  substances use as self-medication form, 19–20
  selective serotonin reuptake inhibitors (SSRIs), 79
  self harm, 177
  self-efficacy support, in motivational interviewing (MI), 61
  self-help group approach, for DD in North America, 205
self-medication
drug-induced psychosis, 141
  hypothesis, in cannabis use, 154
  in schizophrenia people, 19–20
self-report, in stimulant use, 126
sensitisation, 123
to substances, 120
short-lived schizophreniform illness, 120
  significance of dual diagnosis problem, 5–6
sinsemilla, 147
social circumstances
leading to substance misuse in schizophrenia population, 20–21
social difficulties, 21–22
social situations, 21–22
socio-cultural considerations, in North America, 201–203
‘Stages of change’ model, 59, 182–183
change, 183
contemplation, 183
maintenance, 183
pre-contemplation, 182
preparation, 183
relapse, 183
stages of change, in personality disorders, 93–99, See also under Personality disorders
stimulant use
clozapine, 126
drug-induced psychosis and, 117–121
positive symptoms, 119
implications for practice, 125–127
psychiatric symptoms, 125
ratings scales of therapeutic alliance, 125
mental illness and, 121–122
ecstasy, 122
olanzapine, 126
people with existing psychotic illnesses, 122–124
and psychosis, 116–127
self-medicating unpleasant symptoms, 126
self-report, 126
in United Kingdom, 117
stress-vulnerability theory or interaction hypothesis, 154
substance misuse
among women, 130–138
problems, 3–4
assessment, 7
in schizophrenia population, 20–21
general population and, psychotic illnesses, 14–16
social circumstances leading to, 20–21
substance use and psychosis, relationship between, 140–141
substance Use Mental Illness Treatment Team (SUMITT) pilot, 225
suicide, 177
system-wide approach, public health and DD, 182
terminology, 4–5
tetrahydrocannabinol (THC), 148
therapeutic principles, personality disorders, 99–100
treatment, consumer perspectives, 28–29,
32–33
triple diagnosis, 234–235
true drug-induced psychosis, 143
twelve-step programmes, 205
under-reporting, of alcohol misuse in older people, 107
United Kingdom
stimulant use in, 117
United States, DD in, 202–204
Victorian Dual Diagnosis Initiative (VDDI), 225
Wernicke–Korsakoff syndrome, 77
withdrawal states, 142
withdrawal, MA, 168–169
women and DD, 130–138
borderline personality disorder, 131
complex PTSD, 131–132
domestic violence, 135
within female prison service, 135–136
gender differences in DD, 131–133
gender-specific services, 136–137
impact on families, 133–134
Hidden Harm report, 133
personality disorders, 131
PTSD, 131–132